Neurocrine Bio. (NBIX): KOL Expects Significant Uptake of Elagolix in Endometriosis, Tougher Sell in Uterine Fibroids - Jefferies

Jefferies analyst Biren Amin reiterated a Buy rating and $61 price target on Neurocrine Bio. (NASDAQ: NBIX) after hosting a dinner with an endometriosis and uterine fibroids (UF) specialist who shared his views on both markets, including where he sees GnRH antagonist treatment fitting relative to current and emerging treatments.

Amin commented, "In endometriosis, our expert expected significant uptake of elagolix as well as significant growth in the market. For UF, he thought the SPRMs would be in front of GnRH antagonists, but questioned whether tx cycles for SPRMs may hamper uptake."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $44.13 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
• Lockheed Martin (LMT) PT Raised to $487 at Deutsche Bank